TRAVERE THERAPEUTICS, INC. Operating Lease, Liability, Current
TRAVERE THERAPEUTICS, INC. (TVTX) had Operating Lease, Liability, Current of $6.16 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Operating Lease, Liability, Current $6.16M.
- 2026-03-31: Operating Lease, Liability, Current $6.02M.
- 2025-12-31: Operating Lease, Liability, Current $5.88M.
- 2025-09-30: Operating Lease, Liability, Current $5.73M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $6.16M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $6.02M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $5.88M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $5.73M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $5.59M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $5.46M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $5.41M 10-K · filed 2026-02-19 |
| 2024-09-30 | $5.30M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $5.16M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $5.04M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $4.91M 10-K · filed 2025-02-21 |
| 2023-09-30 | $4.78M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $4.66M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $4.54M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.43M 10-K · filed 2024-02-20 |
| 2022-09-30 | $4.23M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $4.12M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $4.01M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $3.91M 10-K · filed 2023-02-23 |
| 2021-09-30 | $3.80M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $2.62M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $1.09M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $357.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $798.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.38M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $2.46M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.61M 10-K · filed 2020-02-24 |
| 2019-09-30 | $2.67M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $2.67M 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |